Symbols / HOTH Stock $0.84 +9.12% Hoth Therapeutics, Inc.
HOTH (Stock) Chart
About
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; and HT-004 for treatment of asthma and allergies using inhalational administration. The company is developing BioLexa Platform, a proprietary, patented, drug compound platform in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. The company was incorporated in 2017 and is headquartered in New York, New York.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 13.04M |
| Enterprise Value | 4.66M | Income | -11.88M | Sales | — |
| Book/sh | 0.54 | Cash/sh | 0.51 | Dividend Yield | — |
| Payout | 0.00% | Employees | 2 | IPO | — |
| P/E | — | Forward P/E | -1.18 | PEG | — |
| P/S | — | P/B | 1.54 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | 7.76 |
| Current Ratio | 8.81 | Debt/Eq | 0.17 | LT Debt/Eq | — |
| EPS (ttm) | -0.83 | EPS next Y | -0.71 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-27 16:00 | ROA | -84.46% |
| ROE | -151.13% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 15.51M |
| Shs Float | 14.96M | Short Float | 4.36% | Short Ratio | 1.55 |
| Short Interest | — | 52W High | 2.12 | 52W Low | 0.66 |
| Beta | 0.55 | Avg Volume | 538.62K | Volume | 118.29K |
| Target Price | $5.00 | Recom | Strong_buy | Prev Close | $0.77 |
| Price | $0.84 | Change | 9.12% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$5.00
Mean price target
2. Current target
$0.84
Latest analyst target
3. DCF / Fair value
$-7.71
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.84
Low
$5.00
High
$5.00
Mean
$5.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-25 | main | D. Boral Capital | Buy → Buy | $5 |
| 2026-03-04 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-12-04 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-11-17 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-08-18 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-07-30 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-07-23 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-06-26 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-06-12 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-04-15 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-04-03 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-03-31 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-03-10 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-03-06 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-03-04 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-02-11 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-01-23 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-01-22 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-01-07 | main | D. Boral Capital | Buy → Buy | $5 |
| 2024-11-04 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
- China patent backs Hoth technology designed to kill mast cells - stocktitan.net ue, 31 Mar 2026 12
- Hoth strikes back against cancer drug skin toxicities, but share price stays frozen - Fierce Biotech hu, 22 Jan 2026 08
- Hoth Therapeutics 10-K: $0 Revenue, $(0.90) EPS, $(12.47)M Net Loss - TradingView Fri, 27 Mar 2026 21
- HOTH: Analyst Jason Kolbert Maintains Buy Rating with $5 Target Price | HOTH Stock News - gurufocus.com hu, 26 Mar 2026 06
- Hoth Therapeutics Files Two Provisional Patent Applications to Expand Product Portfolio - Pharmaceutical Executive Fri, 02 Jan 2026 08
- Hoth bets on AI to speed drug research across 3 disease areas - stocktitan.net hu, 26 Mar 2026 12
- Hoth Therapeutics stock rises after pipeline update - Investing.com Wed, 03 Dec 2025 08
- Hoth Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com Fri, 27 Mar 2026 20
- Hoth Therapeutics' GDNF Treatment Shows Superior Efficacy Over Wegovy, Ozempic In Preclinical Trial - Stocktwits hu, 05 Mar 2026 08
- 3 Under-the-Radar Biotechs Under $5 That Could Soar 200% - MarketBeat ue, 09 Sep 2025 07
- Hoth Therapeutics stock rises after positive interim trial results - Investing.com hu, 22 Jan 2026 08
- Hoth Therapeutics (NASDAQ: HOTH) warns on cash needs and going‑concern risk - stocktitan.net Fri, 27 Mar 2026 20
- Hoth Therapeutics stock rises after expanding AI initiative with NVIDIA - Investing.com Wed, 08 Oct 2025 07
- Cancer-rash cream shows no serious side effects, sustained response - stocktitan.net ue, 24 Mar 2026 12
- Obesity study: Hoth HT-VA tops semaglutide on cholesterol, triglycerides - stocktitan.net ue, 10 Mar 2026 07
Financials
Statement View
| Line Item | Trend | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
8.22
+3.30%
|
7.95
-28.13%
|
11.07
-21.53%
|
14.10
|
| Research And Development |
|
3.25
-13.14%
|
3.74
-24.14%
|
4.93
-34.51%
|
7.53
|
| Selling General And Administration |
|
4.97
+17.90%
|
4.21
-31.33%
|
6.13
-6.66%
|
6.57
|
| General And Administrative Expense |
|
4.97
+17.90%
|
4.21
-31.33%
|
6.13
-6.66%
|
6.57
|
| Salaries And Wages |
|
—
|
—
|
2.59
-14.74%
|
3.04
|
| Other Gand A |
|
4.97
+17.90%
|
4.21
-31.33%
|
6.13
+75.82%
|
3.49
|
| Total Expenses |
|
8.22
+3.30%
|
7.95
-28.13%
|
11.07
-21.53%
|
14.10
|
| Operating Income |
|
-8.22
-3.30%
|
-7.95
+28.13%
|
-11.07
+21.53%
|
-14.10
|
| Total Operating Income As Reported |
|
-8.22
-3.30%
|
-7.95
+28.13%
|
-11.07
+21.53%
|
-14.10
|
| EBITDA |
|
-8.22
-3.30%
|
-7.95
+28.13%
|
-11.07
+21.53%
|
-14.10
|
| Normalized EBITDA |
|
-8.24
-5.74%
|
-7.80
+27.00%
|
-10.68
+23.44%
|
-13.95
|
| Reconciled Depreciation |
|
—
|
—
|
—
|
0.00
|
| EBIT |
|
-8.22
-3.30%
|
-7.95
+28.13%
|
-11.07
+21.53%
|
-14.10
|
| Total Unusual Items |
|
0.03
+117.59%
|
-0.16
+59.28%
|
-0.39
-153.41%
|
-0.15
|
| Total Unusual Items Excluding Goodwill |
|
0.03
+117.59%
|
-0.16
+59.28%
|
-0.39
-153.41%
|
-0.15
|
| Net Income |
|
-8.19
-1.01%
|
-8.11
+28.72%
|
-11.37
+20.55%
|
-14.31
|
| Pretax Income |
|
-8.19
-1.01%
|
-8.11
+28.72%
|
-11.37
+20.55%
|
-14.31
|
| Net Non Operating Interest Income Expense |
|
—
|
0.00
-87.74%
|
0.01
|
0.00
|
| Net Interest Income |
|
—
|
0.00
-87.74%
|
0.01
|
0.00
|
| Interest Income Non Operating |
|
—
|
0.00
-87.74%
|
0.01
|
0.00
|
| Interest Income |
|
—
|
0.00
-87.74%
|
0.01
|
0.00
|
| Other Income Expense |
|
0.03
+117.72%
|
-0.15
+51.03%
|
-0.31
-47.35%
|
-0.21
|
| Other Non Operating Income Expenses |
|
—
|
—
|
0.45
+857.16%
|
-0.06
|
| Gain On Sale Of Security |
|
0.03
+117.59%
|
-0.16
+59.28%
|
-0.39
-153.41%
|
-0.15
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-8.19
-1.01%
|
-8.11
+28.72%
|
-11.37
+20.55%
|
-14.31
|
| Net Income From Continuing Operation Net Minority Interest |
|
-8.19
-1.01%
|
-8.11
+28.72%
|
-11.37
+20.55%
|
-14.31
|
| Net Income From Continuing And Discontinued Operation |
|
-8.19
-1.01%
|
-8.11
+28.72%
|
-11.37
+20.55%
|
-14.31
|
| Net Income Continuous Operations |
|
-8.19
-1.01%
|
-8.11
+28.72%
|
-11.37
+20.55%
|
-14.31
|
| Normalized Income |
|
-8.22
-3.36%
|
-7.95
+27.64%
|
-10.99
+22.43%
|
-14.16
|
| Net Income Common Stockholders |
|
-8.19
-1.01%
|
-8.11
+28.71%
|
-11.37
+20.56%
|
-14.31
|
| Diluted EPS |
|
-1.28
+46.22%
|
-2.38
+74.95%
|
-9.50
+40.70%
|
-16.02
|
| Basic EPS |
|
-1.28
+46.22%
|
-2.38
+74.95%
|
-9.50
+40.70%
|
-16.02
|
| Basic Average Shares |
|
6.38
+87.00%
|
3.41
+184.69%
|
1.20
+34.07%
|
0.89
|
| Diluted Average Shares |
|
6.38
+87.00%
|
3.41
+184.69%
|
1.20
+34.07%
|
0.89
|
| Diluted NI Availto Com Stockholders |
|
-8.19
-1.01%
|
-8.11
+28.71%
|
-11.37
+20.56%
|
-14.31
|
| Earnings From Equity Interest |
|
-0.00
-113.20%
|
0.00
+101.17%
|
-0.38
|
0.00
|
| Preferred Stock Dividends |
|
—
|
—
|
-0.00
|
—
|
| Rent And Landing Fees |
|
—
|
—
|
0.07
+42.59%
|
0.05
|
| Rent Expense Supplemental |
|
—
|
—
|
0.07
+42.59%
|
0.05
|
| Line Item | Trend | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
7.71
-24.70%
|
10.24
+51.54%
|
6.76
-38.47%
|
10.99
|
| Current Assets |
|
7.64
-24.68%
|
10.15
+50.91%
|
6.73
-36.39%
|
10.58
|
| Cash Cash Equivalents And Short Term Investments |
|
7.04
-24.25%
|
9.29
+39.99%
|
6.64
-36.36%
|
10.43
|
| Cash And Cash Equivalents |
|
7.04
-24.25%
|
9.29
+44.55%
|
6.43
-24.71%
|
8.54
|
| Cash Financial |
|
7.04
-24.25%
|
9.29
+44.55%
|
6.43
-24.71%
|
8.54
|
| Other Short Term Investments |
|
—
|
0.00
-100.00%
|
0.21
-88.94%
|
1.89
|
| Receivables |
|
0.05
+0.00%
|
0.05
|
0.00
-100.00%
|
0.05
|
| Other Receivables |
|
0.05
+0.00%
|
0.05
|
—
|
—
|
| Prepaid Assets |
|
0.56
-31.08%
|
0.81
+817.31%
|
0.09
-5.88%
|
0.09
|
| Total Non Current Assets |
|
0.07
-26.65%
|
0.09
+180.50%
|
0.03
-91.95%
|
0.41
|
| Net PPE |
|
0.03
-43.67%
|
0.06
|
0.00
|
—
|
| Gross PPE |
|
0.03
-47.95%
|
0.06
|
0.00
|
—
|
| Accumulated Depreciation |
|
0.00
+100.00%
|
-0.00
|
—
|
—
|
| Properties |
|
0.00
|
0.00
|
—
|
—
|
| Buildings And Improvements |
|
0.03
-47.95%
|
0.06
|
—
|
—
|
| Other Properties |
|
—
|
0.06
|
—
|
—
|
| Investments And Advances |
|
0.04
-1.55%
|
0.04
+13.33%
|
0.03
-91.95%
|
0.41
|
| Long Term Equity Investment |
|
0.04
-1.55%
|
0.04
+13.33%
|
0.03
-91.95%
|
0.41
|
| Total Liabilities Net Minority Interest |
|
0.83
+18.29%
|
0.70
-56.95%
|
1.64
+48.51%
|
1.10
|
| Current Liabilities |
|
0.83
+22.48%
|
0.68
-51.10%
|
1.39
+59.92%
|
0.87
|
| Payables And Accrued Expenses |
|
0.80
+23.55%
|
0.65
-53.17%
|
1.39
+59.92%
|
0.87
|
| Payables |
|
0.41
+1057.76%
|
0.04
-94.88%
|
0.69
+92.54%
|
0.36
|
| Accounts Payable |
|
0.41
+1057.76%
|
0.04
-94.88%
|
0.69
+92.54%
|
0.36
|
| Current Accrued Expenses |
|
0.39
-36.38%
|
0.61
-11.33%
|
0.69
+36.68%
|
0.51
|
| Current Debt And Capital Lease Obligation |
|
0.03
-1.64%
|
0.03
|
—
|
—
|
| Current Capital Lease Obligation |
|
0.03
-1.64%
|
0.03
|
0.00
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
-89.71%
|
0.03
-89.47%
|
0.25
+6.38%
|
0.23
|
| Long Term Debt And Capital Lease Obligation |
|
0.00
-89.71%
|
0.03
|
0.00
|
—
|
| Long Term Capital Lease Obligation |
|
0.00
-89.71%
|
0.03
|
0.00
|
—
|
| Stockholders Equity |
|
6.88
-27.88%
|
9.54
+86.23%
|
5.12
-48.17%
|
9.88
|
| Common Stock Equity |
|
6.88
-27.88%
|
9.54
+86.23%
|
5.12
-48.17%
|
9.88
|
| Capital Stock |
|
0.00
+84.83%
|
0.00
+234.62%
|
0.00
+35.42%
|
0.00
|
| Common Stock |
|
0.00
+84.83%
|
0.00
+234.62%
|
0.00
+35.42%
|
0.00
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
8.04
+84.97%
|
4.35
+233.93%
|
1.30
+35.78%
|
0.96
|
| Ordinary Shares Number |
|
8.04
+84.97%
|
4.35
+233.93%
|
1.30
+35.78%
|
0.96
|
| Additional Paid In Capital |
|
67.28
+8.99%
|
61.73
+22.98%
|
50.20
+15.16%
|
43.59
|
| Retained Earnings |
|
-60.41
-15.68%
|
-52.22
-15.79%
|
-45.10
-33.72%
|
-33.73
|
| Gains Losses Not Affecting Retained Earnings |
|
0.01
-66.75%
|
0.03
+23.88%
|
0.02
+25.13%
|
0.02
|
| Other Equity Adjustments |
|
0.01
-66.75%
|
0.03
+23.88%
|
0.02
+25.13%
|
0.02
|
| Total Equity Gross Minority Interest |
|
6.88
-27.88%
|
9.54
+86.23%
|
5.12
-48.17%
|
9.88
|
| Total Capitalization |
|
6.88
-27.88%
|
9.54
+86.23%
|
5.12
-48.17%
|
9.88
|
| Working Capital |
|
6.81
-28.06%
|
9.47
+77.42%
|
5.34
-45.00%
|
9.71
|
| Invested Capital |
|
6.88
-27.88%
|
9.54
+86.23%
|
5.12
-48.17%
|
9.88
|
| Total Debt |
|
0.03
-43.67%
|
0.06
|
0.00
|
—
|
| Capital Lease Obligations |
|
0.03
-43.67%
|
0.06
|
0.00
|
—
|
| Net Tangible Assets |
|
6.88
-27.88%
|
9.54
+86.23%
|
5.12
-48.17%
|
9.88
|
| Tangible Book Value |
|
6.88
-27.88%
|
9.54
+86.23%
|
5.12
-48.17%
|
9.88
|
| Investmentsin Joint Venturesat Cost |
|
0.04
-1.55%
|
0.04
+13.33%
|
0.03
-91.95%
|
0.41
|
| Non Current Accrued Expenses |
|
—
|
0.00
-100.00%
|
0.25
+6.38%
|
0.23
|
| Non Current Note Receivables |
|
—
|
—
|
—
|
0.00
|
| Notes Receivable |
|
—
|
—
|
0.00
-100.00%
|
0.05
|
| Line Item | Trend | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-6.98
+17.39%
|
-8.45
+9.15%
|
-9.30
+23.10%
|
-12.09
|
| Cash Flow From Continuing Operating Activities |
|
-6.98
+17.39%
|
-8.45
+9.15%
|
-9.30
+23.10%
|
-12.09
|
| Net Income From Continuing Operations |
|
-8.19
-1.01%
|
-8.11
+28.72%
|
-11.37
+20.55%
|
-14.31
|
| Depreciation Amortization Depletion |
|
—
|
—
|
—
|
0.00
|
| Depreciation |
|
—
|
—
|
—
|
0.00
|
| Depreciation And Amortization |
|
—
|
—
|
—
|
0.00
|
| Other Non Cash Items |
|
—
|
-0.28
-908.82%
|
0.03
-63.23%
|
0.09
|
| Stock Based Compensation |
|
0.80
+271.61%
|
0.22
-65.14%
|
0.62
-53.07%
|
1.32
|
| Operating Gains Losses |
|
0.00
-99.72%
|
0.20
-78.31%
|
0.94
+831.73%
|
0.10
|
| Gain Loss On Investment Securities |
|
—
|
0.21
-63.13%
|
0.57
+1257.85%
|
0.04
|
| Unrealized Gain Loss On Investment Securities |
|
—
|
0.21
+274.62%
|
-0.12
-167.73%
|
0.18
|
| Net Foreign Currency Exchange Gain Loss |
|
—
|
—
|
0.00
-100.00%
|
0.06
|
| Change In Working Capital |
|
0.41
+183.15%
|
-0.49
-181.97%
|
0.59
+12.18%
|
0.53
|
| Change In Prepaid Assets |
|
0.25
+18.15%
|
0.21
+5448.01%
|
0.00
+170.98%
|
-0.01
|
| Change In Payables And Accrued Expense |
|
0.15
+121.84%
|
-0.70
-218.64%
|
0.59
+10.33%
|
0.54
|
| Change In Payable |
|
—
|
—
|
—
|
0.54
|
| Change In Account Payable |
|
—
|
—
|
—
|
0.54
|
| Investing Cash Flow |
|
—
|
0.00
-100.00%
|
1.16
+802.55%
|
-0.17
|
| Cash Flow From Continuing Investing Activities |
|
—
|
0.00
-100.00%
|
1.16
+802.55%
|
-0.17
|
| Capital Expenditure |
|
—
|
—
|
-0.07
+36.74%
|
-0.12
|
| Net Investment Purchase And Sale |
|
—
|
0.00
-100.00%
|
1.24
+2653.88%
|
-0.05
|
| Purchase Of Investment |
|
—
|
—
|
0.00
+100.00%
|
-2.56
|
| Sale Of Investment |
|
—
|
0.00
-100.00%
|
1.24
-50.72%
|
2.51
|
| Net Business Purchase And Sale |
|
—
|
—
|
—
|
0.00
|
| Purchase Of Business |
|
—
|
—
|
—
|
0.00
|
| Gain Loss On Sale Of Business |
|
0.00
+113.20%
|
-0.00
-101.17%
|
0.38
|
0.00
|
| Net Intangibles Purchase And Sale |
|
—
|
0.00
+100.00%
|
-0.07
+36.74%
|
-0.12
|
| Purchase Of Intangibles |
|
—
|
0.00
+100.00%
|
-0.07
+36.74%
|
-0.12
|
| Financing Cash Flow |
|
4.74
-58.09%
|
11.32
+87.49%
|
6.04
-66.82%
|
18.19
|
| Cash Flow From Continuing Financing Activities |
|
4.74
-58.09%
|
11.32
+87.49%
|
6.04
-66.82%
|
18.19
|
| Net Common Stock Issuance |
|
1.06
-90.63%
|
11.31
+89.05%
|
5.99
-66.44%
|
17.84
|
| Repurchase Of Capital Stock |
|
—
|
0.00
+100.00%
|
-0.00
|
0.00
|
| Proceeds From Stock Option Exercised |
|
3.68
+156260.93%
|
0.00
|
0.00
-100.00%
|
0.36
|
| Net Other Financing Charges |
|
—
|
—
|
0.05
|
—
|
| Changes In Cash |
|
-2.24
-177.88%
|
2.87
+236.67%
|
-2.10
-135.36%
|
5.94
|
| Effect Of Exchange Rate Changes |
|
-0.02
-179.18%
|
-0.01
+32.05%
|
-0.01
+68.61%
|
-0.03
|
| Beginning Cash Position |
|
9.29
+44.55%
|
6.43
-24.71%
|
8.54
+224.69%
|
2.63
|
| End Cash Position |
|
7.04
-24.25%
|
9.29
+44.55%
|
6.43
-24.71%
|
8.54
|
| Free Cash Flow |
|
-6.98
+17.39%
|
-8.45
+9.87%
|
-9.37
+23.23%
|
-12.21
|
| Common Stock Issuance |
|
1.06
-90.63%
|
11.31
+89.05%
|
5.99
-66.44%
|
17.84
|
| Earnings Losses From Equity Investments |
|
—
|
-0.00
-101.17%
|
0.38
|
0.00
|
| Issuance Of Capital Stock |
|
1.06
-90.63%
|
11.31
+89.02%
|
5.99
-66.44%
|
17.84
|
| Net Preferred Stock Issuance |
|
—
|
0.00
-100.00%
|
0.00
|
0.00
|
| Preferred Stock Issuance |
|
—
|
0.00
-100.00%
|
0.00
|
0.00
|
| Preferred Stock Payments |
|
—
|
0.00
+100.00%
|
-0.00
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-K2026-03-27 View
- 8-K2026-01-16 View
- 10-Q2025-11-12 View
- 8-K2025-10-17 View
- 8-K2025-09-12 View
- 42025-08-28 View
- 8-K2025-08-22 View
- 10-Q2025-08-12 View
- 8-K2025-08-05 View
- 8-K2025-06-24 View
- 8-K2025-06-20 View
- 8-K2025-06-09 View
- 8-K2025-05-16 View
- 10-Q2025-05-12 View
- 8-K2025-05-02 View
- 8-K2025-04-15 View
- 10-K2025-03-28 View
- 8-K2025-03-25 View
- 8-K2025-02-07 View
- 8-K2025-01-24 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|